| abstract |
The invention relates to a polypeptide comprising a humanised antibody or a fragment thereof, wherein the said antibody comprises at least one CDR selected from SEQ ID Nos: 3, 4 5, 6, 7 or 8 or a modified form of any of these, and binds Venezuelan equine encephalitis virus (VEEV) for use in the prophylaxis or treatment of VEEV or Mucambo virus infection in humans, wherein the polypeptide is for administration more than 24 hours and less than 65 hours post-exposure to the virus. Also claimed is a combination of such a polypeptide with a second polypeptide that comprises an anti-VEEV antibody or fragment thereof that binds a different epitope of VEEV; a pharmaceutical composition comprising the same, and methods for preventing or treating a VEEV or Mucambo infection. The antibody may bind the E2h epitope within the E2 glycoprotein of VEEV. |